Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Howard Henick who wrote (6857)	7/30/1998 8:05:00 PM
From: William L. Molair II	Respond to of 17367

I wonder if the investors that just ponied up the 12.5 million dollars to Xoma are covering their investment by shorting the stock? Anyone have access to recent short numbers on XOMA?

To: Howard Henick who wrote (6857)	7/30/1998 10:32:00 PM
From: John Patterson	Read Replies (2) \| Respond to of 17367

Take a look a CORR if you think earnings are the answer for bio-techs. $26/share PRIOR to FDA advisory panel hearing. Panel recommends Integrilin for angioplasty support but not unstable angina, stock gets cut in half. Full FDA OVER RIDES advisory panel and gives full approval for both angioplasty and unstable angina (a huge market). Stock surges to 22.50. That was in April the stock has continued to slide, closed today at 13 15/16. About half of what it sold for prior to advisory panel hearing. CORR also released 2nd quarter earnings a couple of days ago, they earned .38/share (including a 24 million target payment from their partner Shering-Plough. They have also sold 1.4 million worth of Integrilin the last 22 days of the quarter after it was released June 8th. My point is "nobody cares", it's a bio-tech and it's a bear market so even good companies are getting creamed. IMHO!